Search

Your search keyword '"Gironella, Mercedes"' showing total 325 results

Search Constraints

Start Over You searched for: Author "Gironella, Mercedes" Remove constraint Author: "Gironella, Mercedes"
325 results on '"Gironella, Mercedes"'

Search Results

1. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

2. Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study

3. Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma

5. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies

6. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

7. Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real‐world setting.

9. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

10. Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis

11. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

13. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

14. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

15. P-367 High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience

16. P937: CARFILZOMIB, LENALIDOMIDE PLUS DEXAMETHASONE (KRD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: UPDATE ANALYSIS OF REAL-LIFE EXPERIENCE OF GEMMAC GROUP.

18. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

19. Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role

20. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

21. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality

22. #2634 ROLE OF LIGHT CHAIN CLEARANCE IN THE RECOVERY OF RENAL FUNCTION IN MULTIPLE MYELOMA: ANOTHER POINT OF VIEW

23. Kinetics of cellular and humoral immunogenicity and effectiveness of SARS‐CoV ‐2 booster vaccination in hematologic neoplasms

24. Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

25. Benefits of rIX-FP prophylaxis in patients with Haemophilia B: real-world evidence from a Spanish reference centre.

26. Role of light chain clearance in the recovery of renal function in multiple myeloma: another point of view

27. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

28. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance

29. Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM

30. Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature

32. Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease

33. Poster: MM-459 Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis

34. Oral Abstract: MM-459 Safety and Clinical Activity of Belantamab Mafodotin with Lenalidomide Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis

35. MM-488 Iberdomide, Bortezomib, and Dexamethasone (IberVd) in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Results From the CC-220-MM-001 Trial

36. Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study.

38. Safety and clinical activity of belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-6 arm-A interim analysis.

39. Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain

40. Correction: Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role

41. Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints

42. Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies

43. Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development

45. Mastocytosis in the skin accompanied by pseudo‐Kaposi’s sarcoma

47. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

48. Multiple Myeloma and SARS-CoV-2 Infection: Clinical Characteristics and Prognostic Factors of Inpatient Mortality

49. Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis

50. Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature

Catalog

Books, media, physical & digital resources